Nitta Gelatin Co., Ltd. Q1 FY2027 Analysis: Revenue Growth Masks Operating Profit Dip
Nitta Gelatin Co., Ltd. (TSE:4977), a leading global supplier of gelatin and collagen ingredients for food and pharmaceuticals, reported solid top-line growth in its first quarter (Q1) of the fiscal year ending March 2027. While Revenue increased by 8.3% Year-over-year (YoY) to JPY 9.89bn, Operating Profit declined by 5.5% YoY to JPY 1.18bn, though Ordinary Income and Net Profit both posted gains of 1.8% YoY and 10.4% YoY, respectively.
| Metric | Current Period (JPY) | Prior Period (JPY) | Change (%) |
|---|---|---|---|
| Revenue | JPY 9.89bn | JPY 9.137bn | +8.3% |
| Operating Profit | JPY 1.18bn | JPY 1.253bn | -5.5% |
| Ordinary Income | JPY 1.27bn | JPY 1.249bn | +1.8% |
| Net Profit | JPY 690M | JPY 625M | +10.4% |
Nitta Gelatin Co., Ltd. is a major global player in the gelatin market, specializing in high-quality ingredients for food and pharmaceutical applications. The company also ranks second in Japan for collagen peptides production.
The Q1 results indicate robust demand across key segments, highlighted by strong performance in the Collagen Peptide segment (+17.8% YoY) and the Food Material segment (+7.7% YoY), contributing to an overall Revenue increase of 8.3%. However, the decline in Operating Profit (-5.5%) suggests underlying cost pressures or structural challenges impacting core profitability despite higher sales volumes. Conversely, the maintenance of growth in Ordinary Income and Net Profit points toward non-operating gains or favorable adjustments in expense structures supporting the bottom line. The company’s financial stability remains high, evidenced by an Equity Ratio of 57.0%.
Full-Year Guidance
| Metric | Forecast (JPY) | Prior Period Comparison | YoY Change (%) |
|---|---|---|---|
| Revenue | JPY 43.0bn | N/A | +13.0% |
| Operating Profit | JPY 4.70bn | N/A | +0.8% |
| Ordinary Income | JPY 4.80bn | N/A | +0.3% |
| Net Profit | JPY 2,400M | N/A | -26.9% |
The full-year forecast suggests continued revenue expansion (JPY 43.0bn, +13.0% YoY), but the projected growth in Operating Profit (+0.8%) and Ordinary Income (+0.3%) is significantly muted compared to sales expectations. Notably, the forecasted Net Profit shows a substantial decline (-26.9% YoY). The guidance appears cautious regarding core profitability metrics relative to top-line growth.
Key Takeaways for Investors
- Profit Structure Divergence: The divergence between strong Revenue growth and declining Operating Profit, contrasted with stable Ordinary Income growth, warrants close examination of the cost structure and non-operating income components in subsequent reports.
- Full-Year Caution: Investors should pay close attention to the full-year forecast, particularly the significant projected drop in Net Profit (-26.9% YoY), which suggests potential headwinds or specific accounting treatments impacting shareholder returns for the fiscal year ending March 2027.
- Strategic Focus: The company continues its strategy of diversifying revenue streams by enhancing high-value segments like Collagen Peptides, while maintaining a strong balance sheet with an Equity Ratio of 57.0%.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.